Drug intelligence / Profile preview

ciclosporin + mycophenolate mofetil

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

The combination of ciclosporin (also known as cyclosporine A or CsA) and mycophenolate mofetil (MMF) is used as an immunosuppressive regimen primarily to prevent organ transplant rejection and to treat certain autoimmune conditions. Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation by inhibiting the transcription of interleukin-2 and other cytokines. Mycophenolate mofetil is a prodrug of mycophenolic acid that acts as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), leading to selective inhibition of lymphocyte proliferation by blocking de novo guanosine nucleotide synthesis. The combination has synergistic immunosuppressive effects and is commonly used in kidney, heart, and liver transplantation regimens[1][2][5]. It may also be considered for steroid- or calcineurin-inhibitor-resistant nephrotic syndrome such as focal segmental glomerulosclerosis[5].

Brand names
NeoralSandimmuneGengrafCellCept
Other names
cyclosporine ACsAMMF
02

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)CN (Calcineurin)

Beyond the preview

Go deeper on ciclosporin + mycophenolate mofetil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciclosporin + mycophenolate mofetil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call